CM
EBS icon

Castleark Management’s Emergent Biosolutions EBS Stock Holding History

Castleark Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-107,424
Closed -$11.1M – 342
2020
Q3 		$11.1M Buy
+107,424
New +$11.6M 0.44% 58
2014
Q4 		– Sell
-180,225
Closed -$4.55M – 355
2014
Q3 		$4.55M Buy
+180,225
New +$4.13M 0.13% 168
2014
Q2 		– Sell
-180,225
Closed -$4.55M – 322
2014
Q1 		$4.55M Buy
+180,225
New +$4.55M 0.13% 168

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Castleark Management's EBS Position: Q4 2020 in Review

Castleark Management sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 107,424 shares — an estimated $11.1M sold.

Castleark Management first reported a position in EBS in Q1 2014 and held it in 3 quarters. The position peaked at $11.1M in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Castleark Management reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
  • Castleark Management sold 107,424 Emergent Biosolutions shares in Q4 2020, an estimated $11.1M.
  • Castleark Management first reported a position in Emergent Biosolutions in Q1 2014 and held it in 3 quarters.
  • Castleark Management's Emergent Biosolutions position peaked at $11.1M in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Castleark Management's 13F filing for Q4 2020, filed 17 Feb 2021.